[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY2017001PI2 - Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων - Google Patents

Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων

Info

Publication number
CY2017001PI2
CY2017001PI2 CY2017001C CY2017001PC CY2017001PI2 CY 2017001P I2 CY2017001P I2 CY 2017001PI2 CY 2017001 C CY2017001 C CY 2017001C CY 2017001P C CY2017001P C CY 2017001PC CY 2017001P I2 CY2017001P I2 CY 2017001PI2
Authority
CY
Cyprus
Prior art keywords
therapeutics
modulators
pharmacokinetic properties
pharmacokinetic
properties
Prior art date
Application number
CY2017001C
Other languages
English (en)
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39522375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2017001P(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of CY2017001PI2 publication Critical patent/CY2017001PI2/el
Publication of CY2017001PI1 publication Critical patent/CY2017001PI1/el

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CY2017001C 2007-02-23 2017-01-04 Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων CY2017001PI1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90322807P 2007-02-23 2007-02-23
US95871607P 2007-07-06 2007-07-06
EP08743531.9A EP2118082B1 (en) 2007-02-23 2008-02-22 Modulators of pharmacokinetic properties of therapeutics

Publications (2)

Publication Number Publication Date
CY2017001PI2 true CY2017001PI2 (el) 2017-09-13
CY2017001PI1 CY2017001PI1 (el) 2017-09-13

Family

ID=39522375

Family Applications (9)

Application Number Title Priority Date Filing Date
CY20161101075T CY1118292T1 (el) 2007-02-23 2016-10-25 Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων
CY20161101152T CY1118219T1 (el) 2007-02-23 2016-11-09 Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων
CY20161101168T CY1118227T1 (el) 2007-02-23 2016-11-14 Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων
CY20161101170T CY1118232T1 (el) 2007-02-23 2016-11-15 Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων
CY2017003C CY2017003I2 (el) 2007-02-23 2017-01-04 Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων
CY2017001C CY2017001PI1 (el) 2007-02-23 2017-01-04 Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων
CY2017002C CY2017002I2 (el) 2007-02-23 2017-01-04 Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων
CY20201100220T CY1122761T1 (el) 2007-02-23 2020-03-13 Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων
CY2020011C CY2020011I2 (el) 2007-02-23 2020-06-05 Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων

Family Applications Before (5)

Application Number Title Priority Date Filing Date
CY20161101075T CY1118292T1 (el) 2007-02-23 2016-10-25 Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων
CY20161101152T CY1118219T1 (el) 2007-02-23 2016-11-09 Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων
CY20161101168T CY1118227T1 (el) 2007-02-23 2016-11-14 Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων
CY20161101170T CY1118232T1 (el) 2007-02-23 2016-11-15 Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων
CY2017003C CY2017003I2 (el) 2007-02-23 2017-01-04 Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων

Family Applications After (3)

Application Number Title Priority Date Filing Date
CY2017002C CY2017002I2 (el) 2007-02-23 2017-01-04 Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων
CY20201100220T CY1122761T1 (el) 2007-02-23 2020-03-13 Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων
CY2020011C CY2020011I2 (el) 2007-02-23 2020-06-05 Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων

Country Status (32)

Country Link
US (7) US8148374B2 (el)
EP (5) EP3689353A1 (el)
JP (9) JP4881446B2 (el)
KR (2) KR101664154B1 (el)
CN (2) CN103435570B (el)
AP (2) AP2986A (el)
AR (1) AR065439A1 (el)
AU (1) AU2008218186C1 (el)
BR (1) BRPI0807581A2 (el)
CA (1) CA2678907C (el)
CY (9) CY1118292T1 (el)
DK (2) DK3150586T3 (el)
EA (1) EA019893B1 (el)
ES (6) ES2603617T3 (el)
FI (1) FI2487161T4 (el)
FR (4) FR17C1002I2 (el)
HK (1) HK1137451A1 (el)
HR (5) HRP20161476T4 (el)
HU (6) HUE031707T2 (el)
IL (1) IL200550A0 (el)
LT (9) LT2487162T (el)
LU (1) LUC00156I2 (el)
MX (1) MX2009008935A (el)
NO (4) NO2017002I1 (el)
NZ (1) NZ579802A (el)
PL (3) PL3150586T3 (el)
PT (6) PT2487162T (el)
SG (2) SG183059A1 (el)
SI (1) SI3150586T1 (el)
TW (1) TWI533868B (el)
WO (1) WO2008103949A1 (el)
ZA (1) ZA200905882B (el)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE490788T1 (de) 2003-04-25 2010-12-15 Gilead Sciences Inc Antivirale phosphonate analoge
PT2258376T (pt) * 2004-07-27 2019-05-31 Gilead Sciences Inc Análogos fosfonatados de compostos inibidores do vih
EA020489B1 (ru) * 2006-07-07 2014-11-28 Джилид Сайэнс, Инк. Модуляторы фармакокинетических свойств лекарственных средств
WO2008027932A2 (en) * 2006-08-31 2008-03-06 Abbott Laboratories Cytochrome p450 oxidase inhibitors and uses thereof
DK2487161T4 (da) 2007-02-23 2024-06-24 Gilead Sciences Inc Modulatorer af farmakokinetiske egenskaber af terapeutika
LT2487162T (lt) * 2007-02-23 2016-11-10 Gilead Sciences, Inc. Terapinių agentų farmakokinetinių savybių moduliatoriai
WO2009067225A2 (en) * 2007-11-20 2009-05-28 Concert Pharmaceuticals, Inc. Boceprevir derivatives for the treatment of hcv infections
ES2555209T3 (es) * 2008-01-04 2015-12-29 Gilead Sciences, Inc. Inhibidores del citocromo P450
HUE026380T2 (en) * 2008-05-02 2016-06-28 Gilead Sciences Inc Use of solid carrier particle
NZ590075A (en) * 2008-07-08 2012-12-21 Gilead Sciences Inc citrate, malonate and succinate salts of the HIV inhibitor ethyl N-[(S)({ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy} methyl)phenoxyphosphinoyl]-L-alaninate
SG172060A1 (en) 2008-12-09 2011-07-28 Gilead Sciences Inc Modulators of toll-like receptors
SG10201706215UA (en) * 2009-02-06 2017-08-30 Gilead Sciences Inc Tablets for combination therapy
AU2015200637C1 (en) * 2009-02-06 2017-08-03 Gilead Sciences, Inc. Tablets for combination therapy
UA108738C2 (uk) * 2009-04-03 2015-06-10 Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки
WO2010151672A2 (en) * 2009-06-26 2010-12-29 Georgetown University Amino acid derived ureas
SMT201800290T1 (it) 2010-01-27 2018-07-17 Viiv Healthcare Co Terapia antivirale
NL2005306C2 (nl) * 2010-09-02 2012-03-05 Tersia Nederland B V Koppelstuk voor meerlaagse leidingen, lasapparaaat voor het verbinden van het koppelstuk met meerlaagse leidingen, werkwijze van koppelen en een samenstel verkregen via de werkwijze.
WO2012045007A1 (en) 2010-10-01 2012-04-05 Gilead Sciences, Inc. Method of preparation of (4 - {4 -acetylamino- 2 - [3- ( 2 - isopropyl - thiazol - 4 - ylmethyl) - 3 -methyl - ureido] - butyryl amino} -1 -benzyl- 5 -phenyl- pentyl) -carbamic acid thiazol - 5 - ylmethyl ester
EP2640362B2 (en) * 2010-11-19 2021-12-01 Gilead Sciences, Inc. Therapeutic compositions comprising rilpivirin hcl and tenovofir disoproxil fumarate
US20130274254A1 (en) 2010-12-21 2013-10-17 Gilead Sciences, Inc. Inhibitors of cytochrome p450 (cyp3a4)
WO2012088153A1 (en) * 2010-12-21 2012-06-28 Gilead Sciences, Inc. Inhibitors of cytochrome p450
WO2012088156A1 (en) 2010-12-21 2012-06-28 Gilead Sciences, Inc. Inhibitors of cytochrome p450
EP2472320A2 (en) 2010-12-30 2012-07-04 Rohm and Haas Electronic Materials LLC Compositions comprising base-reactive component and processes for photolithography
WO2012151165A1 (en) * 2011-05-02 2012-11-08 Gilead Sciences, Inc. Amorphous solid salts
HUE035241T2 (en) 2011-07-07 2018-05-02 Janssen Sciences Ireland Uc Darunavir combination formulations
JP5651275B2 (ja) 2011-08-16 2015-01-07 ギリアード サイエンシス インコーポレーテッド テノホビルアラフェナミドヘミフマレート
AU2013204731C1 (en) * 2012-02-03 2017-08-31 Gilead Sciences, Inc. Therapeutic compounds
WO2013115916A1 (en) * 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections
CA2862344A1 (en) 2012-02-03 2013-08-08 Gilead Science, Inc. Methods and intermediates for preparing pharmaceutical agents
CN103694196A (zh) * 2012-09-27 2014-04-02 上海迪赛诺化学制药有限公司 细胞色素p450单加氧酶抑制剂中间体及其制法和用途
WO2014057498A2 (en) 2012-10-08 2014-04-17 Mylan Laboratories Ltd. Process for the preparation of cobicistat intermediates
JP2015534973A (ja) * 2012-10-23 2015-12-07 シプラ・リミテッド 抗レトロウイルス医薬組成物
UA123572C2 (uk) 2012-12-21 2021-04-28 Гіліад Сайєнсіз, Інк. Поліциклічні карбамоїлпіридонові сполуки та їх фармацевтичне застосування
US20160200716A1 (en) 2012-12-26 2016-07-14 Assia Chemical Industries Ltd. Cobicistat dichlohydrate salt
NO2865735T3 (el) 2013-07-12 2018-07-21
AU2014286993B2 (en) 2013-07-12 2018-10-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of HIV infections
DK3054926T3 (en) 2013-10-07 2018-10-29 Bristol Myers Squibb Holdings Ireland FORMULATION OF ATAZANAVIR AND COBICISTAT FOR HIV TREATMENT
ES2689654T3 (es) 2013-12-03 2018-11-15 Mylan Laboratories Ltd. Preparación de productos intermedios de cobicistat
WO2015145324A1 (en) 2014-03-25 2015-10-01 Mylan Laboratories Ltd Process for the preparation of cobicistat
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (el) 2014-06-20 2018-06-23
TWI733652B (zh) 2014-07-11 2021-07-21 美商基利科學股份有限公司 用於治療HIV之toll樣受體調節劑
SG11201700341PA (en) * 2014-07-17 2017-02-27 Chdi Foundation Inc Methods and compositions for treating hiv-related disorders
CN106715431A (zh) 2014-09-16 2017-05-24 吉利德科学公司 Toll样受体调节剂的固体形式
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
SG11201705069YA (en) 2014-12-26 2017-07-28 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
BR112017020837A2 (pt) 2015-04-02 2018-07-03 Gilead Sciences, Inc. compostos de carbamoilpiridona policíclicos e seu uso farmacêutico
CN105198829B (zh) * 2015-08-15 2017-10-31 浙江永宁药业股份有限公司 一种可比司他中间体的制备方法及其中间体和用途
CN107513046B (zh) * 2016-06-15 2019-12-13 江苏欧信制药有限公司 一种可比司他的合成方法
WO2018026835A1 (en) * 2016-08-04 2018-02-08 Gilead Sciences, Inc. Cobicistat for use in cancer treatments
EP3496719B1 (en) 2016-08-08 2023-06-14 Hetero Labs Limited A multi-class anti-retroviral composition
WO2018029561A1 (en) 2016-08-08 2018-02-15 Hetero Labs Limited Anti-retroviral compositions
KR101908853B1 (ko) * 2017-05-17 2018-10-16 경북대학교 산학협력단 아세틸시코닌을 유효성분으로 함유하는 시토크롬 p450 동효소 억제용 조성물
ES2969496T3 (es) 2017-08-01 2024-05-20 Gilead Sciences Inc Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2- il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales
AU2018378832B9 (en) 2017-12-07 2021-05-27 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN109912530A (zh) * 2017-12-13 2019-06-21 上海奥博生物医药技术有限公司 一种可比司他原料杂质的制备方法
CN111989316B (zh) * 2018-01-30 2023-09-08 潘贝拉治疗股份有限公司 用于生产(6s,15s)-3,8,13,18-四氮杂二十烷-6,15-二醇的方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN117105928B (zh) * 2023-08-22 2024-03-26 上海蓝木化工有限公司 一种蛋白酶抑制剂及其制备方法

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US199851A (en) * 1878-01-29 Improvement in circular saws
US108617A (en) * 1870-10-25 Improvement in ore-pulverizers
US127689A (en) * 1872-06-11 Improvement in differential pulley-blocks
US191319A (en) * 1877-05-29 Improvement in stoves
US143314A (en) * 1873-09-30 Improvement in condenser-tube fastenings
US115665A (en) * 1871-06-06 Improvement in folding-steps for carriages
US77295A (en) * 1868-04-28 theqdoee krausch
US181902A (en) * 1876-09-05 Improvement in bell toys
US99902A (en) * 1870-02-15 1870-02-15 Improvement in adjustable dials for travelers watches
US3400197A (en) 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
US3882114A (en) 1967-10-26 1975-05-06 Oreal N-(morpholinomethyl carbamyl) cysteamine and glycine
GB1241024A (en) 1968-10-29 1971-07-28 Boehringer Sohn Ingelheim Pharmaceutical tablet base and a process for its manufacture
NL149711B (nl) 1970-06-15 1976-06-15 Sumitomo Chemical Co Werkwijze voor het vervaardigen van pillen, alsmede de aldus vervaardigde pillen.
GB1339764A (en) 1971-03-29 1973-12-05 Ici Ltd Pyridine derivatives
CH586568A5 (el) 1972-04-10 1977-04-15 Hoffmann La Roche
US3957774A (en) 1972-04-17 1976-05-18 L'oreal N-morpholinomethyl-n-'-substituted ethyl and propylureas
DE2845326C2 (de) 1978-10-18 1985-05-23 Beiersdorf Ag, 2000 Hamburg Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
US5142056A (en) 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
HU186777B (en) 1981-07-09 1985-09-30 Magyar Tudomanyos Akademia Process for producing complex-forming agents of crown-ether base and ionoselective membranelektrodes containing them
US4603143A (en) 1983-05-02 1986-07-29 Basf Corporation Free-flowing, high density, fat soluble vitamin powders with improved stability
GB8413191D0 (en) 1984-05-23 1984-06-27 Beecham Group Plc Pharmaceutical composition
FR2631620B1 (fr) 1988-05-19 1990-07-27 Rhone Poulenc Chimie Nouvelle silice precipitee absorbante et composition a base de cette s ilice
US5362912A (en) 1989-05-23 1994-11-08 Abbott Laboratories Process for the preparation of a substituted diaminodiol
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5539122A (en) 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
EP0428849A3 (en) 1989-09-28 1991-07-31 Hoechst Aktiengesellschaft Retroviral protease inhibitors
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
IE913840A1 (en) 1990-11-20 1992-05-20 Abbott Lab Retroviral protease inhibiting compounds
GB9109862D0 (en) 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
JPH06127981A (ja) 1992-03-03 1994-05-10 Fuainiteii Kk 複合複層ガラス及びそれを使用した窓
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
DK1302468T3 (da) 1992-12-29 2009-03-02 Abbott Lab Fremgangsmåder og mellemprodukter til fremstilling af forbindelser, der inhiberer retroviral protease
WO1995005808A1 (en) 1993-08-24 1995-03-02 Abbott Laboratories Oil-based tableting method
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5567823A (en) 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5763464A (en) 1995-11-22 1998-06-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Retroviral agents containing anthranilamide, substituted benzamide and other subunits, and methods of using same
JP4064476B2 (ja) 1996-03-29 2008-03-19 エラワン ファーマスーティカル リサーチ アンドラボラトリー カンパニー リミテッド 二酸化珪素を有する球状凝集した澱粉
US6348216B1 (en) 1996-06-10 2002-02-19 Knoll Pharmaceutical Company Ibuprofen and narcotic analgesic compositions
US6361794B1 (en) 1996-06-12 2002-03-26 Basf Corporation Method of making ibuprofen and narcotic analgesic composition
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5939090A (en) 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
JP4494539B2 (ja) 1997-02-28 2010-06-30 ディーエスエム アイピー アセッツ ビー.ブイ. 流動自由な乾燥粒子
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
FR2767071B1 (fr) 1997-08-06 1999-09-10 Rhodia Chimie Sa Composition comprenant un liquide absorbe sur un support a base de silice precipitee
AU2010299A (en) * 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
FR2773994B1 (fr) 1998-01-23 2002-10-11 Univ Nice Sophia Antipolis Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central
JP4027535B2 (ja) 1998-05-26 2007-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 脂溶性薬物を含有した粉末
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
DE60029219T2 (de) * 1999-06-04 2007-06-28 Abbott Laboratories, Abbott Park Verbesserte arzneizubereitungen enthaltend ritonavir
NZ518580A (en) 1999-10-06 2004-01-30 Us Gov Health & Human Serv Hexahydrofuro[2,3-B]furan-3-YL-N- {3-[1,3-benzodioxol-5-ylsulfonyl) (isobutyl) amino]-1-benzyl-2-hydroxypropyl} carbamate as retroviral protease inhibitor
CA2311734C (en) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
US6448245B1 (en) 2000-05-04 2002-09-10 The United States Of America As Represented By The Department Of Health And Human Services Methods of and compounds for inhibiting calpains
US20030035834A1 (en) 2000-05-26 2003-02-20 Pawan Seth Sustained release verapamil pharmaceutical composition free of food effect and a method for alleviating food effect in drug release
RU2281757C2 (ru) 2000-09-19 2006-08-20 Дайити Фармасьютикал Ко., Лтд. Фармацевтическая композиция
US7056951B2 (en) 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
US6524615B2 (en) 2001-02-21 2003-02-25 Kos Pharmaceuticals, Incorporated Controlled release pharmaceutical composition
DE10112651A1 (de) 2001-03-16 2002-09-19 Degussa Inhomogene Kieselsäuren als Trägermaterial
SK286536B6 (sk) 2001-05-01 2008-12-05 Pfizer Products Inc. Spôsob granulácie za sucha na prípravu farmaceutickej kompozície
DE10126163A1 (de) 2001-05-30 2002-12-05 Degussa Pharmazeutische Zubereitungen
JP4570357B2 (ja) 2001-07-06 2010-10-27 ライフサイクル ファーマ エー/エス 制御された凝集
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7193065B2 (en) 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
US7815936B2 (en) 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
AU2002219964A1 (en) 2001-11-29 2003-06-17 Penwest Pharmaceutical Company Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US20030206978A1 (en) 2001-11-29 2003-11-06 Bob Sherwood Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US7285566B2 (en) 2002-01-07 2007-10-23 Erickson John W Resistance-repellent retroviral protease inhibitors
AU2003216049B2 (en) 2002-01-17 2008-07-17 Merck Sharp & Dohme Corp. Hydroxynaphthyridinone carboxamides useful as HIV integrase inhibitors
US6926906B2 (en) 2002-02-20 2005-08-09 M./S. Strides, Inc. Orally administrable pharmaceutical formulation
US6726448B2 (en) 2002-05-15 2004-04-27 General Electric Company Ceramic turbine shroud
PA8576201A1 (es) 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
DE10250711A1 (de) 2002-10-31 2004-05-19 Degussa Ag Pharmazeutische und kosmetische Zubereitungen
DE60329318D1 (de) 2002-11-20 2009-10-29 Japan Tobacco Inc 4-oxochinolinverbindungen und deren verwendung als hiv-integrase-inhibitoren
US7189416B2 (en) 2002-11-23 2007-03-13 Glykon Technologies Group, Llc Method for stable and controlled delivery of (-)-hydroxycitric acid
JP2004184681A (ja) 2002-12-03 2004-07-02 Konica Minolta Holdings Inc 熱現像感光材料
AU2004206821C1 (en) 2003-01-14 2009-10-01 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
CN1758901B (zh) 2003-02-19 2010-04-28 生命周期药物公司 硅石或硅石衍生物作为吸附材料的用途
FR2851918B1 (fr) 2003-03-06 2006-06-16 Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
JP4018664B2 (ja) 2003-04-30 2007-12-05 第一三共株式会社 安定化固形製剤
DE10337198A1 (de) 2003-08-13 2005-03-17 Degussa Ag Träger auf Basis von Granulaten, die aus pyrogen hergestelltem Siliciumdioxiden hergestellt sind
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
JP2005075826A (ja) 2003-08-29 2005-03-24 Boehringer Ingelheim Internatl Gmbh 多孔質シリカ担体を含有する徐放性製剤
JP2005091988A (ja) 2003-09-19 2005-04-07 Konica Minolta Medical & Graphic Inc 熱現像感光材料及び画像形成方法
EP1675576A1 (en) 2003-10-03 2006-07-05 LifeCycle Pharma A/S A method for preparing modified release pharmaceutical compositions
US20050096390A1 (en) 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and pravastatin
US20050095287A1 (en) 2003-10-29 2005-05-05 Matharu Amol S. Fosinopril composition
US7834043B2 (en) 2003-12-11 2010-11-16 Abbott Laboratories HIV protease inhibiting compounds
US20070298108A1 (en) 2004-03-01 2007-12-27 Peter Svete Pharmaceutical Formulation
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
WO2005105040A2 (en) 2004-04-26 2005-11-10 Micelle Products, Inc. Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications
BRPI0401742B8 (pt) 2004-05-13 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
JP4629104B2 (ja) 2004-05-21 2011-02-09 日本たばこ産業株式会社 4−オキソキノリン誘導体および抗hiv剤を含む併用剤
JP2006003701A (ja) 2004-06-18 2006-01-05 Konica Minolta Medical & Graphic Inc 熱現像感光材料および画像形成方法
EP1765297A2 (en) 2004-06-28 2007-03-28 LifeCycle Pharma A/S Porous tablets as carriers for liquid formulations
JP5142714B2 (ja) 2004-07-06 2013-02-13 アボット・ラボラトリーズ Hivプロテアーゼ阻害薬のプロドラッグ
AR045841A1 (es) 2004-09-28 2005-11-16 Richmond Sa Com Ind Y Financie Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.
WO2006044968A2 (en) 2004-10-19 2006-04-27 Achillion Pharmaceuticals, Inc. Combination therapy for treating viral infections
US7786153B2 (en) * 2005-03-02 2010-08-31 Abbott Laboratories Inc. Compounds that are useful for improving pharmacokinetics
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
US20070014854A1 (en) 2005-07-15 2007-01-18 Ilan Zalit Novel granulation process
JP2009521523A (ja) 2005-12-27 2009-06-04 ジュビラント・オルガノシス・リミテッド 口中溶解性医薬組成物およびその製造方法
US20090233964A1 (en) 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
SG170796A1 (en) 2005-12-30 2011-05-30 Gilead Sciences Inc Us Methods for improving the pharmacokinetics of hiv integrase inhibitors
EA018606B1 (ru) 2006-01-05 2013-09-30 Велоксис Фармасьютикалз А/С Распадающиеся загружаемые таблетки
JPWO2007097333A1 (ja) 2006-02-20 2009-07-16 アサヒビール株式会社 顆粒、錠剤およびそれらの製造方法
MX2008012225A (es) 2006-03-23 2008-12-03 Schering Corp Combinaciones de inhibidores de proteasa de virus de hepatitis c e inhibidores de isoenzima 3a4 del citocromo p450, y metodos de tratamiento relacionados con las mismas.
EA020489B1 (ru) * 2006-07-07 2014-11-28 Джилид Сайэнс, Инк. Модуляторы фармакокинетических свойств лекарственных средств
BRPI0714265A2 (pt) 2006-08-10 2013-04-16 Cipla Ltd composiÇço oral sàlida, processo para preparar uma composiÇço oral sàlida, uso de uma composiÇço e mÉtodo para tratar hiv
WO2008027932A2 (en) 2006-08-31 2008-03-06 Abbott Laboratories Cytochrome p450 oxidase inhibitors and uses thereof
US20090281132A1 (en) 2006-09-04 2009-11-12 Kiran Kumar Narsaiah Velaveni Pharmaceutical formulation for use in hiv therapy
US7749537B2 (en) 2006-12-04 2010-07-06 Scolr Pharma, Inc. Method of forming a tablet
LT2487162T (lt) * 2007-02-23 2016-11-10 Gilead Sciences, Inc. Terapinių agentų farmakokinetinių savybių moduliatoriai
CN103356622A (zh) 2007-06-29 2013-10-23 吉里德科学公司 治疗用组合物及其用途
TW200914011A (en) 2007-06-29 2009-04-01 Gilead Sciences Inc Therapeutic compositions and methods
WO2009008989A1 (en) 2007-07-06 2009-01-15 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
NZ586317A (en) 2007-12-27 2012-10-26 Baxter Int Method and compositions for specifically detecting physiologically acceptable polymer molecules
HUE026380T2 (en) * 2008-05-02 2016-06-28 Gilead Sciences Inc Use of solid carrier particle
SG10201706215UA (en) 2009-02-06 2017-08-30 Gilead Sciences Inc Tablets for combination therapy
EP2238979A1 (en) 2009-04-06 2010-10-13 LEK Pharmaceuticals d.d. Active pharmaceutical ingredient adsorbed on solid support
JP6127981B2 (ja) 2012-01-10 2017-05-17 Jnc株式会社 発光層用材料およびこれを用いた有機電界発光素子
AU2013204731C1 (en) 2012-02-03 2017-08-31 Gilead Sciences, Inc. Therapeutic compounds

Also Published As

Publication number Publication date
CY2020011I1 (el) 2020-11-25
PL2487161T3 (pl) 2017-03-31
LT2487162T (lt) 2016-11-10
LTPA2016039I1 (lt) 2017-01-10
ES2603645T3 (es) 2017-02-28
EP2487161B2 (en) 2024-06-05
FI2487161T4 (fi) 2024-06-06
LUC00156I2 (el) 2021-02-17
US20120237478A1 (en) 2012-09-20
PL3150586T3 (pl) 2020-06-01
ZA200905882B (en) 2018-12-19
PT2487162T (pt) 2016-11-23
EP3689353A1 (en) 2020-08-05
ES2602784T3 (es) 2017-02-22
NO2017003I1 (no) 2017-01-12
CY1118292T1 (el) 2017-06-28
HUE031707T2 (en) 2017-07-28
AP3915A (en) 2016-11-29
CN103435570A (zh) 2013-12-11
PL2487162T3 (pl) 2017-03-31
US20170158647A1 (en) 2017-06-08
AP2013007042A0 (en) 2013-08-31
WO2008103949A1 (en) 2008-08-28
KR20090122261A (ko) 2009-11-26
EP2487161A1 (en) 2012-08-15
LTC2487163I2 (lt) 2022-06-27
US20150139948A1 (en) 2015-05-21
CY2017003I1 (el) 2017-06-28
PT2487166T (pt) 2016-10-17
JP6147282B2 (ja) 2017-06-14
JP2019059790A (ja) 2019-04-18
CY1118227T1 (el) 2017-06-28
NZ579802A (en) 2012-04-27
PT2487161T (pt) 2016-11-10
JP2010519314A (ja) 2010-06-03
LTPA2016038I1 (lt) 2017-01-10
US20140017199A1 (en) 2014-01-16
EP3150586A1 (en) 2017-04-05
CY2017003I2 (el) 2017-06-28
PT3150586T (pt) 2020-03-31
HUE029866T2 (en) 2017-03-28
ES2603617T3 (es) 2017-02-28
SI3150586T1 (sl) 2020-03-31
JP2014088441A (ja) 2014-05-15
HRP20161502T1 (hr) 2016-12-16
LT2487163T (lt) 2016-10-25
US8486942B2 (en) 2013-07-16
PL2487161T5 (pl) 2024-09-09
US20100189687A1 (en) 2010-07-29
LTC3150586I2 (lt) 2022-05-10
PT2487163T (pt) 2016-11-21
FR17C1000I2 (fr) 2019-03-22
CA2678907C (en) 2014-06-17
AR065439A1 (es) 2009-06-10
HRP20200349T1 (hr) 2020-06-12
ES2601820T5 (es) 2024-10-31
KR101664154B1 (ko) 2016-10-10
CY1118219T1 (el) 2017-06-28
TW200904419A (en) 2009-02-01
HRP20161428T1 (hr) 2016-12-16
AU2008218186A1 (en) 2008-08-28
HRP20161476T4 (hr) 2024-07-05
EP2487161B1 (en) 2016-08-10
LTC2487166I2 (lt) 2021-10-11
US9891239B2 (en) 2018-02-13
AU2008218186B2 (en) 2014-01-23
LT2487166T (lt) 2016-11-10
LTPA2020508I1 (lt) 2020-06-25
TWI533868B (zh) 2016-05-21
CY2017001PI1 (el) 2017-09-13
EP4403221A3 (en) 2024-10-09
JP2016121193A (ja) 2016-07-07
CN101679325A (zh) 2010-03-24
NO2020011I1 (no) 2020-06-05
JP2021001236A (ja) 2021-01-07
AP2986A (en) 2014-09-30
EP3150586B1 (en) 2020-01-08
PT2118082E (pt) 2014-12-12
HUE029843T2 (en) 2017-04-28
HRP20161371T1 (hr) 2016-12-02
LT2487161T (lt) 2016-11-10
DK3150586T3 (da) 2020-02-17
EP2118082B1 (en) 2014-10-01
CY2020011I2 (el) 2020-11-25
JP2016172773A (ja) 2016-09-29
AU2008218186C1 (en) 2014-07-17
HUS2000013I1 (hu) 2020-06-29
LTC2487162I2 (lt) 2022-06-27
NO2017002I2 (no) 2017-01-12
AP2009004964A0 (en) 2009-10-31
JP2017171695A (ja) 2017-09-28
LTPA2016040I1 (lt) 2017-01-10
FR17C1001I2 (fr) 2019-05-17
EP4403221A2 (en) 2024-07-24
HUS1600054I1 (hu) 2017-01-30
EA200901155A1 (ru) 2010-02-26
DK2487166T3 (en) 2017-02-20
HRP20161476T1 (hr) 2016-12-16
ES2525454T3 (es) 2014-12-23
KR20150056665A (ko) 2015-05-26
MX2009008935A (es) 2009-11-02
US20080207620A1 (en) 2008-08-28
EA019893B1 (ru) 2014-07-30
CY1118232T1 (el) 2017-06-28
FR20C1021I1 (fr) 2020-07-31
JP2011231132A (ja) 2011-11-17
KR101577698B1 (ko) 2015-12-15
FR17C1002I2 (fr) 2019-03-22
JP6147388B2 (ja) 2017-06-14
IL200550A0 (en) 2010-05-17
NO2017002I1 (no) 2017-01-12
CY2017002I1 (el) 2017-06-28
HUE029842T2 (en) 2017-04-28
US8148374B2 (en) 2012-04-03
NO2017001I1 (no) 2017-01-12
BRPI0807581A2 (pt) 2014-07-01
JP4881446B2 (ja) 2012-02-22
CA2678907A1 (en) 2008-08-28
CN101679325B (zh) 2013-08-28
LT3150586T (lt) 2020-03-10
SG183059A1 (en) 2012-08-30
JP5554300B2 (ja) 2014-07-23
LUC00156I1 (el) 2020-06-02
CN103435570B (zh) 2015-06-10
FR17C1002I1 (fr) 2017-03-17
HK1137451A1 (en) 2010-07-30
JP6192776B2 (ja) 2017-09-06
SG10201705929QA (en) 2017-08-30
CY1122761T1 (el) 2020-11-25
FR17C1001I1 (fr) 2017-03-17
ES2601820T3 (es) 2017-02-16
JP2015078241A (ja) 2015-04-23
ES2779826T3 (es) 2020-08-20
EP2118082A1 (en) 2009-11-18
FR17C1000I1 (fr) 2017-03-17
CY2017002I2 (el) 2017-06-28
US20160069915A1 (en) 2016-03-10

Similar Documents

Publication Publication Date Title
CY2017001PI2 (el) Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων
DK2049506T4 (da) Modulatorer af farmakokinetiske egenskaber af terapeutik
HK1143144A1 (en) Modulators of pharmacokinetic properties of therapeutics
HUS1600052I1 (hu) Terápiás szerek farmakokinetikai paramétereinek modulálása